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In recent years major advances in the understanding of the
basic mechanisms of anti-inflammatory and immunomodula-
tory functions of antibodies have taken place. Immunoglob-
ulin G is playing an ever-expanding role in the treatment of
immunoinflammatory and neurologic disorders. Novel con-
cepts in the pathogenesis of certain neurologic disorders and
the possible role of natural antibodies and modulation by
immunoglobulintherapyhaveemerged.Thesewerediscussed
at the first International Forum on Immunoglobulin Research
at Fort Lauderdale, FL, on November 19–22, 2009.
Intravenous immunoglobulin (IVIG) regulates immune
responses by a number of complex mechanisms. These
include its effects on inflammatory and immunomodulatory
functions of dendritic cells (DCs; e.g., maturation of DCs,
generation of Treg, and induction of tolerance) and the
activation of different FcRs. Furthermore, different mecha-
nisms of IVIG may predominate in different diseases, thus
explainingitsbeneficialeffectsinadiversegroupofdisorders.
Srini Kaveri (Paris, France) discussed the mechanisms of
immunomodulatory effects of IVIG on DCs. However, it is
critical to know the in vivo effects of IVIG on DC–Tc e l l
interactions. Studies of immunological synapses using two-
photonmicroscopyshouldbeabletodefinethe invivoeffects
of IVIG. Alan Lazarus (Toronto, Canada), in a murine ITP
m o d e lu s i n gt h ea d o p t i v et r a n s f e ro fI V I G - t r e a t e dl e u k o c y t e s
or DCs, demonstrated that the therapeutic effect of IVIG may
be mediated by specific effector cells. IVIG, following
binding to DCs, upregulates the activation of FcR, whereas
in the recipient, inhibitory FcR appears to be necessary.
Therefore, activated DCs may produce a factor that stimulates
inhibitory FcR in the recipient.
Sialylation of IgG Fc plays an important role in the anti-
inflammatory effects of IVIG. In a K/BxN serum-transfer
model of arthritis, IVIG inhibited swelling and inflamma-
tory cell infiltrate, and the removal of glycan or sialic acid
abrogated the anti-inflammatory effects of IVIG. Robert
Anthony (New York, NY, USA) and his group generated
fully recombinant sialylated IgG1 Fc with enhanced
potency. Marginal zone monocytes appear to be the target
cells. FcRs are not required for sialylated Fc effects on
macrophages. These sialylated Fcs bind to SIGN-R1 on
macrophages, which produce a factor that in turn upregu-
lates FcγRIIb. The nature of the factor(s) remains to be
determined. Genetic deletion of SIGN-R1 abrogates the
anti-inflammatory effect of IVIG or sialylated Fc fragments.
Friedrich Altmann (Vienna, Austria) presented structural
requirements of IVIG (IgG) for binding to the lectin
Sambucus nigra agglutinin (SNA). Twelve percent to 13%
of IVIG bind to SNA. Binding of IVIG to the lectin was
mediated by FAB glycosylation. Two sialic acids are
required for SNA binding of glycan in the Fc region. This
may suggest that double sialylation imposes changes of the
protein conformation, which could be relevant for biolog-
ical interactions. An interesting concept has emerged with
regard to IgA FcR. Renato Monteiro (Paris, France)
delineated the mechanisms whereby one FcαR-1 could
mediate both the anti-inflammatory properties of mono-
meric IgA and the proinflammatory properties of polymeric
or aggregated IgA.
Intravenous immunoglobulin appears to have both pro-
apoptotic and anti-apoptotic effects. Both of these effects
target cell type and concentrations of IVIG may be
determining factors. Hans-Uwe Simon (Bern, Switzerland)
discussed the effects of IVIG on Fas-mediated apoptosis in
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trations inhibit apoptosis, whereas high concentrations
increased apoptosis (annexin V). In PMN, GM-CSF, and
interferon-γ increased the efficiency and potency of IVIG-
mediated apoptosis, whereas in eosinophils, IL-5 potentiat-
ed IVIG-induced apoptosis. The presence of anti-Siglec-9
autoantibodies appear to be responsible for chemokine-
augmented cell death. Anti-Siglec antibodies are in dimeric
form (anti-Siglec-anti-Id Siglec antibody). Neuraminidase
treatment of IVIG has no effect. It remains to be determined
whether these antibodies are natural antibodies. Further-
more, there is a need for in-depth analysis of apoptotic
pathways (death receptor, mitochondrial, and the ER path-
ways of apoptosis) to understand underlying mechanisms of
the beneficial effects of IVIG in certain disorders. This is
particularly important with Alzheimer's disease because
misfolded proteins trigger ER stress-induced apoptosis.
Several IVIG clinical trials in AD are currently taking
place.
Natural antibodies/autoantibodies (antibodies present
before external antigen challenge) are produced by B1 cells
and are made primarily from immunoglobulin genes
without major somatic mutation. These antibodies are
predominantly IgM and include a basic set of autoanti-
bodies with low-affinity reactivity for multiple specificities;
this set cross-reacts with common bacterial antigens,
usually carbohydrate in nature. Natural antibodies may be
antigen-specific; however, they are polyreactive. This may
be due to the relative ubiquitous expression of target
epitopes. However, epitopes recognized by natural anti-
bodies remain to be characterized. Natural antibodies are
predominantly IgM isotypes; IgG and IgA natural autoanti-
bodies also occur. IgA natural autoantibodies are primarily
found in secretory IgA. Natural antibodies (autoantibodies)
provide three major functions: host defense, housekeeping,
and immune homeostasis. The preliminary excitation of
cells by autoantigens provides bacterial protection, espe-
cially because the polymeric nature of CHO antigens will
mean that the IgM antibodies, although of low affinity, will
bind with high avidity to the microbe (host defense).
Natural antibodies may act as transporting agents that are
responsible for scavenging effete body components (house-
keeping). Natural antibodies also prevent the stimulation of
autoreactive cells in the conventional B2 cell population
either by masking autoantigen epitopes or by overall
idiotypic regulation (homeostatic role).
More recently, the role and mechanisms of natural
antibodies (autoantibodies) in the regulation of inflamma-
tion, allograft rejection, and remyelination of neuronal
tissue have been delineated. Peter Lobo (Charlottesville,
VA, USA) discussed a role of naturally occurring IgM
antileukocyte antibodies (reacting with macrophages, PMN,
and T cells). These antibodies, which are increased in acute
inflammatory states, are of low binding affinity and kill
leukocytes at cold temperature. Their physiological func-
tions include protection from renal allograft and inhibition
of T cell activation and cytokine production. These anti-
bodies bind to CD4 T cells. Recently, human IgM Fc
receptor (FcμR) has been identified. This receptor contains
conserved Ser and Tyr residues in its cytoplasmic tail, but
none of the Tyr residues match the immunoreceptor
tyrosine-based activation, inhibitory, or switch motif. FcμR
is expressed on CD4
+ T cells and B cells. It is differentially
regulated in that cross-linking results in the activation of B
cells but in the inhibition of T cell activation. This may be
helpful in understanding some of the mechanisms of natural
IgM antibodies. Brian O'Nuallain (Dublin, Ireland) demon-
strated that Aβ-reactive natural IgG autoantibodies are
present in almost all plasma and IVIG samples. These
antibodies had minimal binding to Aβ monomers; however,
they had good affinity for fibrils. Antibodies in IVIG cross-
react with the conformational epitopes of Aβ peptide.
Sudhir Paul (Houston, TX, USA) discussed the properties
of natural catalytic antibodies and reaction mechanisms
involved in Aβ hydrolysis. Arthur Warrington (Rochester,
NY, USA) presented data on the role of IgM natural
antibodies in remyelination and data on the recombinant
natural IgM antibody; however, the molecular characteriza-
tion of target epitopes remains to be defined. Christoph
Binder (Vienna, Austria) elegantly described a role of
natural IgM antibodies in inflammation using an athero-
sclerosis model. This model is characterized by the
accumulation of oxidized lipoproteins and apoptotic cells,
which both contain various oxidation-specific neoepitopes.
A majority of umbilical cord natural IgM antibodies react
with these epitopes.
Intravenous immunoglobulin has been used in a variety
of inflammatory and autoimmune neuropathies. Richard
Hughes (London, UK) reviewed the incidence, prevalence,
and healthcare costs for the treatment of chronic inflamma-
tory demyelinating polyneuropathy (CIDP). He presented
data from Cochrane Reviews, which suggest that IVIG,
steroids, and plasma exchange are effective short-term
therapies for CIDP. Clinical trial data also suggest that
IVIG should be started at an initial dose of 2 g/kg and
followed by 1 g/kg every 3 weeks; in addition, at least two
doses should be given to decide whether a patient is a
responder or nonresponder to IVIG. Jan Lünemann (Zurich,
Switzerland) presented data that show the expression of
FcγRIIB (inhibitory receptor) on peripheral blood naive B
cells in patients with CIDP is lower than in controls and
fails to be upregulated as B cells progress from naive to the
memory compartment. Furthermore, FcγRIIB promoter
polymorphism, which is associated with reduced promoter
activity, was overrepresented in CIDP. Following IVIG
therapy, FcγRIIB expression on B cells and monocytes was
S2 J Clin Immunol (2010) 30 (Suppl 1):S1–S3upregulated and associated with a clinical response to IVIG.
Pieter van Doorn (Rotterdam, The Netherlands) reviewed
the clinical features and course of disease in Gullain-Barré
syndrome and presented data on the efficacy of IVIG. He
also identified that patients who had a minor increase in
serum IgG levels following standard IVIG recovered
significantly slower. Leonard van den Berg (Utrecht, The
Netherlands) reviewed the clinical spectrum in multifocal
motor neuropathy (MMN). He presented data of clinical
outcomes following IVIG therapy, which highlighted the
importance of early treatment to prevent axonal degenera-
tion and more severe outcomes. His data also suggest that
the effect of IVIG in MMN may at least be in part
complement-mediated. Helen Chapel (Oxford, UK) dis-
cussed dosing, monitoring, compliance, and self-infusion of
IVIG in MMN and CIDP.
Immune activation is necessary and sufficient to sustain
experimental chronic pain. Spinal cord glial cell activation
is critical to sustain sensory sensitization, and peripheral
immune activation may contribute to such sensitization so
that minor peripheral stimuli become painful in disorders
such as fibromyalgia and complex regional pain syndrome
(CRPS). Currently, randomized controlled trials of IVIG are
ongoing in CRPS, painful peripheral neuropathy, and
trigeminal neuralgia. Andreas Goebel (Liverpool, UK)
reviewed various chronic pain syndromes and presented
data from the recently completed randomized controlled
trial on low-dose treatment in long-standing CRPS, which
demonstrated good efficacy. IVIG has been effective in
reducing pain intensity in patients with post-polio syn-
drome. He also reported the beneficial effect of both
intrathecal and IVIG in an experimental model of spinal
cord injury (SCI).
Autism is a heterogeneous multifactorial disorder with
genetic, environmental, and immunological factors that
appear to play a role in its pathogenesis. A number of
immunological changes, which appear to be present in a
subset of autistic children, include deficiency of IgG, IgG
subclasses and IgA, and the presence of autoantibodies
against neuronal antigens (Sudhir Gupta, Irvine, CA, USA).
Two important features include increased inflammatory
responses as evidenced by increased levels of chemokine
and cytokine, both in the peripheral blood as well as in the
CNS and tissue of the CNS, and the evidence of
autoimmunity. Most interesting are the autism maternal
antibodies against neural antigens. It is critical to define
epitopes, which are targets of these antibodies, and then
look at those epitope-specific antibodies in children with
autism. Data on open-label trials of IVIG are conflicting:
Beneficial effects are shown in 3 separate trials of 63
patients and 2 open trials of 15 patients (1 open trial had
suboptimal dosing and 1 to 6 infusions at 6 weeks interval)
that did not show any beneficial effect. Because of these
conflicting data, it is important to plan a well-designed,
double-blind study to determine the effectiveness of IVIG
in autism. A good rationale for such a trial exists because of
the disorder's association with antibody deficiency, autoim-
munity, and inflammation.
Ion channels are essential for the basic physiological
functions of excitable cells and immune cells. More than
340 human genes appear to encode ion channels, and
mutations in more than 60 ion channel genes are known to
cause human disorders known as channelopathies. Channe-
lopathies, involving voltage-gated Na
+ channels, Cl
- chan-
nels, voltage-gated Ca
++ channels, neuronal voltage-gated
K
+ channels, inward rectified K
+ channels linked, and
others, have been reported in a number of neuromuscular
disorders. It also appears that some of the antibody-
mediated diseases of the nervous system may be due to
antibodies directed against ion channels. Angela Vincent
(Oxford, UK) gave an excellent description of various
channelopathies in which serum antibodies are directed
against voltage-gated K
+ channels or ligand-gated channels
such as NMDA, AMPA, and glycine receptors. Some of the
K
+ channel antibodies are directed against closely related
proteins such as CASPR2 (a cell surface adhesion mole-
cule). Antibody levels in the CSF are lower than in the
serum; however, they are synthesized in the brain. Some of
these disorders responded to IVIG, plasma exchange, and
steroid treatment. During SCI, primary injury is a result of
mechanical trauma, whereas secondary injury is caused by
neuroinflammation as a result of the secretion of a number
of inflammatory molecules, including pro-inflammatory
cytokines and reactive oxygen species by locally recruited
leukocytes and microglia. Michael Fehlings (Toronto,
Canada) presented data from an SCI model in rats in which
he demonstrated that IgG treatment reduces secondary
inflammatory damage and improves hind limb function.
This provided a rationale to investigate a neuroprotective
role of Ig therapy in SCI.
Taking into consideration the role of natural IgM anti-
bodies/autoantibodies and monomeric IgA in the inhibition
of inflammation and autoimmunity, it is prudent to explore a
possibility of treating some of these disorders with plasma
preparations enriched in IgM or IgA. The definition of
human IgM FcR may help in understanding the basic
physiological mechanisms and mechanisms for the role of
IgM natural antibodies in certain disorders. It is anticipated
that as we continue to learn more about the mechanisms of
action of immunoglobulins, their therapeutic use will expand
into greater administration by different routes.
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